Document and Entity Information |
Feb. 13, 2023 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K/A |
| Amendment Flag | true |
| Amendment Description | Explanatory Note On February 13, 2023, MAIA Biotechnology, Inc. (the “Company”) filed a Current Report on Form 8-K to furnish a copy of the Company’s press release announcing its intention to initiate its second Phase 2 clinical trial evaluating THIO. On the same day, the Company updated the press release to include an additional model with pre-clinical data. This amended Current Report on Form 8-K is being filed solely to furnish the updated press release. |
| Document Period End Date | Feb. 13, 2023 |
| Entity Registrant Name | MAIA Biotechnology, Inc. |
| Entity Central Index Key | 0001878313 |
| Entity Emerging Growth Company | true |
| Entity Ex Transition Period | false |
| Entity File Number | 001-41455 |
| Entity Incorporation, State or Country Code | DE |
| Entity Tax Identification Number | 83-1495913 |
| Entity Address, Address Line One | 444 West Lake Street, Suite 1700 |
| Entity Address, City or Town | Chicago |
| Entity Address, State or Province | IL |
| Entity Address, Postal Zip Code | 60606 |
| City Area Code | 312 |
| Local Phone Number | 416-8592 |
| Entity Information, Former Legal or Registered Name | N/A |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock |
| Trading Symbol | MAIA |
| Security Exchange Name | NYSEAMER |